Helicobacter pylori

From Aaushi
Jump to navigation Jump to search

Introduction

First described in 1983 by Marshall & Warren in relation to histologic gastritis. The first successful therapy for H pylori (bismuth-based triple therapy for 2 weeks) was described in 1991.

Response to therapy has been shown for peptic ulcer disease & gastric lymphoma.

Epidemiology

  • H. pylori occurs worldwide
  • reservoir of its infection & its mode of transmission are unknown
  • most infection with H.pylori is acquired during childhood
  • prevalence of gastritis associated with H. pylori increases with age

Pathology

Genetics

  • genetic variation in the IFNGR1 gene is associated with susceptibility to Helicobacter pylori infection

Clinical manifestations

Laboratory

* patients should stop proton pump inhibitors 1-2 weeks prior to laboratory testing since proton pump inhibitors suppress growth of the organism

Diagnostic procedures

Complications

Management

* initial treatments of choice[25]

* use of 1/2 dose clarithromycin in combination therapy associated with lower risk of adverse effects (29% vs 44%) & similar eradication rate (82% vs 83%)[35]

* esomeprazole dosed QD[3]

More general terms

Additional terms

References

  1. Clinical Diagnosis & Management by Laboratory Methods, 19th edition, J.B. Henry (ed), W.B. Saunders Co., Philadelphia, PA. 1996, pg 1160
  2. Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 319-321
  3. 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 15, 16, 17, 18, 19. American College of Physicians, Philadelphia 1998, 2006, 2009, 2012, 2015, 2018, 2021.
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  4. 4.0 4.1 Journal Watch 20(16):130, 2000 Yamagata et al 160:1962, 2000
  5. Journal Watch 20(17):136-37, 2000
  6. 6.0 6.1 Journal Watch 20(16):131, 2000 Braden B et al Pediatrics 106:115, 2000
  7. 7.0 7.1 Prescriber's Letter 8(4):21 2001
  8. 8.0 8.1 Journal Watch 21(19):151, 2001 Uemura et sl N Engl J Med 345:784, 2001
  9. Prescriber's Letter 8(11):65 2001
  10. 10.0 10.1 10.2 Prescriber's Letter 9(3):16 2002
  11. 11.0 11.1 Journal Watch 22(5):35, 2002 Huang J-Q et al, Lancet 359:14, 2002 Chan FKL et al, Lancet 359:9, 2001 Pounder RE, Lancet 359:3, 2001
  12. 12.0 12.1 Journal Watch 22(6):45, 2002 Treiber et al, Arch Intern Med 162:153, 2002 (MALCOR study)
  13. 13.0 13.1 Journal Watch 22(7):55, 2002 Vairi et al, Ann Intern Med 136:280, 2002
  14. 14.0 14.1 14.2 Journal Watch 23(21):168, 2003 Veldhuyzen van Zanten S, Fedorak RN, Lambert J, Cohen L, Vanjaka A. Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. Am J Gastroenterol 98:1963, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/14499772
    Kearney DJ, Liu CF, Crump C, Brousal A. The effect of a Helicobacter pylori treatment strategy on health care expenditures in patients with peptic ulcer disease and dyspepsia. Am J Gastroenterol 98:1952, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/14499771
  15. 15.0 15.1 McMahon BJ, Hennessy TW, Bensler JM, Bruden DL, Parkinson AJ, Morris JM, Reasonover AL, Hurlburt DA, Bruce MG, Sacco F, Butler JC. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 139:463, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/13679322
    Sjolund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med 139:483, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/13679325
  16. Journal Watch 25(7):58, 2005 Megraud F; European Paediatric Task Force on Helicobacter pylori. Comparison of non-invasive tests to detect Helicobacter pylori infection in children and adolescents: results of a multicenter European study. J Pediatr. 2005 Feb;146(2):198-203. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15689908
  17. 17.0 17.1 Lane JA, Murray LJ, Noble S, Egger M, Harvey IM, Donovan JL, Nair P, Harvey RF. Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial. BMJ. 2006 Jan 28;332(7535):199-204. Epub 2006 Jan 20. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16428249
    Delaney BC. Who benefits from Helicobacter pylori eradication? BMJ. 2006 Jan 28;332(7535):187-8. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16439372
  18. 18.0 18.1 Prescriber's Letter 13(5): 2006 Levofloxacin for persistent Helicobacter pylori infection Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220512&pb=PRL (subscription needed) http://www.prescribersletter.com
  19. 19.0 19.1 Jarbol DE, Kragstrup J, Stovring H, Havelund T, Schaffalitzky de Muckadell OB. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. Am J Gastroenterol. 2006 Jun;101(6):1200-8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16771937
  20. 20.0 20.1 You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, Ma JL, Pan KF, Liu WD, Hu Y, Crystal-Mansour S, Pee D, Blot WJ, Fraumeni JF Jr, Xu GW, Gail MH. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006 Jul 19;98(14):974-83. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16849680
  21. 21.0 21.1 Kamangar F et al, Opposing risks of gastric cardia and non cardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 2006, 98:1445 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17047193
  22. 22.0 22.1 22.2 22.3 22.4 Prescriber's Letter 14(6): 2007 H. Pylori Treatment Regimens Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=230604&pb=PRL (subscription needed) http://www.prescribersletter.com
    Prescriber's Letter 14(11): 2007 H. Pylori Treatment Regimens Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=231113&pb=PRL (subscription needed) http://www.prescribersletter.com
  23. Prescriber's Letter 17(12): 2010 COMMENTARY: H. Pylori Treatment: Is Quadruple Therapy Making a Comeback? CHART: H. Pylori Treatment Regimens GUIDELINES: American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=261204&pb=PRL (subscription needed) http://www.prescribersletter.com
  24. 24.0 24.1 24.2 Malfertheiner P et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011 Feb 22 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21345487
  25. 25.0 25.1 25.2 Prescriber's Letter 19(2): 2012 COMMENTARY: H. Pylori Treatment: An Update CHART: H. Pylori Treatment Regimens GUIDELINES: American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection (2007) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=280222&pb=PRL (subscription needed) http://www.prescribersletter.com
  26. 26.0 26.1 ARUP Consult: Helicobacter pylori The Physician's Guide to Laboratory Test Selection & Interpretation https://www.arupconsult.com/content/helicobacter-pylori
    Helicobacter pylori Testing Algorithm https://arupconsult.com/algorithm/helicobacter-pylori-testing-algorithm
  27. 27.0 27.1 Gisbert JP et al. Long-term follow-up of 1,000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding. Am J Gastroenterol 2012 Aug; 107:1197. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22613904
  28. 28.0 28.1 28.2 Liou J-M et al Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2012 Nov 15 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23158886
    Greenberg ER and Chey WD. Defining the role of sequential therapy for H. pylori infection. Lancet 2012 Nov 15; PMID: https://www.ncbi.nlm.nih.gov/pubmed/23158881
  29. Chan FKL et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013 Mar; 144:528. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23333655
  30. 30.0 30.1 Liang X et al. Efficacy of bismuth-based quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone- resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013 Jul; 11:802 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23376004 <Internet> http://www.cghjournal.org/article/S1542-3565(13)00116-X/abstract
  31. 31.0 31.1 31.2 Mueller PS N Engl J Med Journal Watch. September 12, 2013 Massachusetts Medical Society http://www.jwatch.org
    Gatta L et al. Global eradication rates for Helicobacter pylori infection: Systematic review and meta-analysis of sequential therapy. BMJ 2013 Aug 7; 347:f4587 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23926315 <Internet> http://www.bmj.com/content/347/bmj.f4587
  32. 32.0 32.1 Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007 Aug;102(8):1808-25. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17608775
  33. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med. 2010 Apr 29;362(17):1597-604 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20427808
  34. 34.0 34.1 Ford AC et al Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014;348:g3174 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24846275 <Internet> http://www.bmj.com/content/348/bmj.g3174
  35. 35.0 35.1 Harb AH et al. Systematic review and meta-analysis: Full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2015 May 24 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26011564
  36. 36.0 36.1 Li BZ, P Threapleton DE, Wang JW et al Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ 2015;351:h4052 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26290044 <Internet> http://www.bmj.com/content/351/bmj.h4052
    Braden B The best and worst treatments for Helicobacter pylori BMJ 2015;351:h4146 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26290321 <Internet> http://www.bmj.com/content/351/bmj.h4146
  37. 37.0 37.1 Luther J, Chey WD, Saad RJ. A clinician's guide to salvage therapy for persistent Helicobacter pylori infection. Hosp Pract (1995). 2011 Feb;39(1):133-40. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21441768
  38. 38.0 38.1 Lee YC, Chiang TH, Chou CK et al. Association between Helicobacter pylori eradication and gastric cancer incidence: A systematic review and meta-analysis. Gastroenterology 2016 Jan 30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26836587 Free Article
  39. 39.0 39.1 39.2 39.3 39.4 Liou JM, Fang YJ, Chen CC et al Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet Oct 18, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27769562 <Internet> http://thelancet.com/journals/lancet/article/PIIS0140-6736(16)31409-X/fulltext
    Megraud F, Gisbert JP Towards effective empirical treatment for Helicobacter pylori eradication. Lancet Oct 18, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27769561 <Internet> http://thelancet.com/journals/lancet/article/PIIS0140-6736(16)31657-9/fulltext
  40. Malfertheiner P, Megraud F, O'Morain CA et al Management of Helicobacter pylori infection-the Maastricht V/ Florence Consensus Report. Gut. 2016 Oct 5. pii: gutjnl-2016-312288. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27707777
  41. Nyssen OP, McNicholl AG, Megraud F et al Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2016 Jun 28;(6):CD009034. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27351542
  42. 42.0 42.1 Lopes AI, Vale FF, Oleastro M. Helicobacter pylori infection - recent developments in diagnosis. World J Gastroenterol. 2014 Jul 28;20(28):9299-313. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25071324 Free PMC Article
  43. 43.0 43.1 Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017 Feb;112(2):212-239. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28071659
  44. 44.0 44.1 Crowe SE Helicobacter pylori Infection. N Engl J Med 2019; 380:1158-1165. March 21. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30893536 https://www.nejm.org/doi/full/10.1056/NEJMcp1710945
  45. Rothaus C. Helicobacter pylori Infection NEJM Resident 360. March 20, 2019 https://resident360.nejm.org/content_items/helicobacter-pylori-infection
  46. Nam SY, Park BJ, Nam JH, Kook MC. Effect of Helicobacter pylori eradication and high-density lipoprotein on the risk of de novo gastric cancer development. Gastrointest Endosc 2019 Apr 26. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31034810 https://www.giejournal.org/article/S0016-5107(19)31659-1/pdf
    Nam SY, Park BJ, Ryu KH, Nam JH. Effect of Helicobacter pylori eradication on the regression of gastric polyps in National Cancer Screening Program. Korean J Intern Med. 2018 May;33(3):506-511. Epub 2017 Dec 14. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29232943 Free PMC Article
  47. 47.0 47.1 47.2 Li WQ, Zhang JY, Ma JL et al Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ 2019;366:l5016 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31511230 Free Article https://www.bmj.com/content/366/bmj.l5016
  48. 48.0 48.1 48.2 48.3 48.4 48.5 48.6 NEJM Knowledge+ Gastroenterology
  49. 49.0 49.1 Yan TL, Wang JH, He XJ, et al. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial. Am J Gastroenterol. 2023 Dec 11 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37975609 https://journals.lww.com/ajg/fulltext/9900/ten_day_vonoprazan_amoxicillin_dual_therapy_vs.935.aspx

Patient information

Helicobacter pylori disease patient information

Database